We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Assay Detects Urinary Proteins in Bladder Cancer

By LabMedica International staff writers
Posted on 08 Jul 2013
Print article
Image: Synergy HT Multi-Mode microplate reader (Photo courtesy of Biotek).
Image: Synergy HT Multi-Mode microplate reader (Photo courtesy of Biotek).
A high-throughput assay has been developed for the detection of tyrosine-phosphorylated proteins (TPPs) in urine of bladder cancer patients.

Urinary TPPs appear to be a potential cancer marker for the detection of early stages of bladder cancer, but the development of methods to perform the evaluation of their diagnostic performances and their clinical validation is crucial.

Oncologists at the University of Turin Medical School (Turin, Italy) collected urine specimens from 23 bladder cancer patients and 43 healthy volunteers. There were 19 males and 4 females with bladder cancer with a mean age of 67.65 ± 10.63. The scientists developed an immobilized metal affinity chromatography (IMAC) system that was miniaturized in a 96 well format. Luminescence, visible, and infrared fluorescence antibody-based detection methods were comparatively evaluated.

The luminescence end-point detection was performed by means of a Synergy HT Multi-Mode microplate reader (Biotek; Winooski, VT, USA) and infrared (IR) fluorescence detection was performed with the Odyssey Infrared Imaging System (LI-COR Biosciences; Lincoln, NE, USA). Due to their low abundance, both a phosphoprotein enrichment step and very sensitive detection methods are required to detect TPPs in urine samples. To pursue high throughput, reproducibility and cost containment, which are required for bladder cancer screening programs. The scientists coupled the preanalytical IMAC procedure with high sensitive detection phases using either infrared fluorescence or chemiluminescence in an automated platform.

The assay represents the first quantitative and high throughput method for the measurement of TPPs in urine. Preliminary evaluation of the sensitivity and the specificity was 87% and 95% respectively, which confirmed the excellent diagnostic performances of TPPs as bladder cancer marker. The authors concluded that their method had optimized the measurement of TPP levels in urine samples, integrating the preanalytical and analytical phases in a 96 well format and with the use of affordable detection methods. This method is now feasible to be applied to a large number of patients and high-risk subjects to establish its actual diagnostic and predictive power. The study was published in the June 2013 issue of the journal Biochimica et Biophysica Acta.

Related Links:

University of Turin Medical School
Biotek
LI-COR Biosciences


New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Molecular Diagnostics

view channel
Image: Screening for prostate cancer with first-line MRI is less cost-effective than first-line PSA testing (Photo courtesy of Adobe Stock)

First-Line PSA Testing More Cost-Effective Than First-Line MRI for Prostate Cancer Screening

Current prostate cancer (PCa) screening protocols typically begin with prostate-specific antigen (PSA) testing, which, if elevated, may lead to further assessment using multiparametric magnetic resonance... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
LGC Clinical Diagnostics